Every 10-Q that Brainstorm Cell Therapeutics I (BCLI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BCLI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCLI filings page.
Brainstorm Cell Therapeutics Inc. reported continued operating losses while advancing its NurOwn® ALS program. For the six months ended June 30, 2026, the company recorded a net loss of $5.98 million, driven by $1.73 million in research and development and $3.93 million in general and administrative expenses. Operating cash outflow was $2.22 million, partially offset by $2.15 million of financing inflows from private placements and new short‑term borrowings.
The balance sheet is highly strained. As of June 30, 2026, Brainstorm held only $22 thousand in cash and cash equivalents and $209 thousand including restricted cash, against $12.39 million in current liabilities, resulting in total assets of $0.79 million and a stockholders’ deficit of $11.60 million. Management explicitly states that recurring losses, limited cash, and dependence on raising additional capital raise substantial doubt about the company’s ability to continue as a going concern.
Strategically, the company continues to focus on NurOwn for ALS. It has withdrawn its prior BLA after an FDA advisory committee voted that data did not demonstrate substantial evidence of effectiveness, but subsequently obtained FDA Special Protocol Assessment agreement and CMC alignment for a planned Phase 3b registrational trial intended to support a future marketing application.
Brainstorm Cell Therapeutics Inc. reported another quarterly loss and remains under significant financial strain. For the three months ended March 31, 2026, the company recorded a net loss of $2,127 thousand, down from $2,864 thousand a year earlier, driven by lower research and development and general and administrative spending.
Total assets were only $755 thousand against $11,764 thousand of liabilities, resulting in a stockholders’ deficit of $11,009 thousand. Cash and cash equivalents were just $15 thousand at quarter-end, with additional restricted cash of $191 thousand, underscoring severe liquidity pressure.
Operating activities used $1,320 thousand of cash, partially offset by $1,250 thousand from financing, including a $970 thousand private placement and new short-term loans. Management explicitly states that recurring losses, minimal cash, reliance on equity and debt financing, and outstanding convertible and other short-term notes raise substantial doubt about the company’s ability to continue as a going concern.
BrainStorm Cell Therapeutics (BCLI) filed its Q3 2025 Form 10‑Q. The company reported a nine‑month net loss of $7.9 million and a Q3 loss of $2.1 million. Cash and cash equivalents were $5 thousand with total cash, cash equivalents and restricted cash of $236 thousand at period end. Total assets were $1.38 million against current liabilities of $9.02 million, leaving a stockholders’ deficit of $7.69 million.
Management disclosed substantial doubt about the company’s ability to continue as a going concern. On July 18, 2025, trading moved to the OTCQB after Nasdaq delisted the stock for failing the minimum stockholders’ equity requirement. During the first nine months, BCLI raised funds via an ATM program (gross $4.47 million), facilitated warrant exercises of 1,381,383 shares under an inducement agreement, and completed a debt‑for‑equity swap of 281,250 shares for $450 thousand of payables.
Operating cash outflow was $6.24 million for the nine months, largely offset by $6.10 million of financing inflows. Subsequent to quarter‑end, on Oct 31, 2025, the company issued a $182,400 promissory note, receiving $155,000 in proceeds.